FDA Approves Easy-To-Use Naloxone: Antidote to Zohydro?
This article was originally published in RPM Report
Executive Summary
FDA’s recent approval of an auto-injection form of naloxone may be an opportunity to change the public perception of the agency’s priorities in the opioid and prescription drug abuse debate.
You may also be interested in...
Zogenix Zohydro Launch Will Test FDA’s Balanced Approach On Opioid Pain Reviews
FDA approved Zogenix’ single-entity hydrocodone product following a negative advisory committee meeting, and is facing ongoing opposition as the drug’s launch begins. The agency argues the risk is consistent with other extended-release opioids – and abuse-deterrent technology is too new to require.
Naloxone Could Go OTC
A House hearing on prescription abuse highlighted a potential OTC switch: naloxone for opioid overdose.
Drug Shortage Could Be Addressed By ‘Resilience Rating’ From Private Entity Under HHS Plan
US HHS is proposing a public-private partnership to assign ratings to manufacturers based on quality/resilience of supply, tied to a purchasing incentive program for providers. The non-agency approach may be key to overcoming industry and political objections.